Establishment Labs (NASDAQ:ESTA) Posts Quarterly Earnings Results, Beats Estimates By $0.13 EPS

Establishment Labs (NASDAQ:ESTA) posted its quarterly earnings data on Tuesday. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.13, FiscalAI reports. The firm had revenue of $64.62 million for the quarter, compared to the consensus estimate of $63.80 million. Establishment Labs had a negative return on equity of 235.45% and a negative net margin of 43.45%.

Establishment Labs Price Performance

Shares of NASDAQ:ESTA opened at $74.96 on Tuesday. The firm has a market cap of $2.18 billion, a price-to-earnings ratio of -26.39 and a beta of 0.99. The firm has a fifty day moving average price of $70.88 and a 200 day moving average price of $57.41. Establishment Labs has a fifty-two week low of $26.56 and a fifty-two week high of $78.25. The company has a debt-to-equity ratio of 15.06, a quick ratio of 2.10 and a current ratio of 3.33.

Analysts Set New Price Targets

ESTA has been the topic of a number of recent analyst reports. Citigroup raised their target price on shares of Establishment Labs from $62.00 to $75.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a research report on Monday, December 29th. Mizuho lifted their target price on shares of Establishment Labs from $85.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Needham & Company LLC reaffirmed a “buy” rating and issued a $84.00 target price on shares of Establishment Labs in a report on Monday, January 12th. Finally, Canaccord Genuity Group raised their price target on Establishment Labs from $72.00 to $85.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $78.86.

Institutional Investors Weigh In On Establishment Labs

A number of hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. increased its stake in Establishment Labs by 117.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock worth $59,145,000 after acquiring an additional 438,206 shares during the last quarter. Viking Global Investors LP purchased a new position in shares of Establishment Labs in the second quarter valued at $14,669,000. Soleus Capital Management L.P. bought a new stake in Establishment Labs in the second quarter worth $9,050,000. Summit Partners Public Asset Management LLC increased its position in Establishment Labs by 87.1% in the third quarter. Summit Partners Public Asset Management LLC now owns 430,160 shares of the company’s stock worth $17,632,000 after purchasing an additional 200,255 shares during the last quarter. Finally, Nantahala Capital Management LLC raised its stake in Establishment Labs by 11.1% during the third quarter. Nantahala Capital Management LLC now owns 1,973,492 shares of the company’s stock valued at $80,893,000 after purchasing an additional 197,962 shares in the last quarter. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.